eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2023
vol. 18
 
Share:
Send email
Share:
abstract:
Original paper

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

Gerson Domingues
1
,
Decio Chinzon
2
,
Joaquim Prado P. Moraes-Filho
2
,
Juliana Tosta Senra
3
,
Marcos Perrotti
3
,
Schlioma Zaterka
2

  1. Internal Medicine – Gastroenterology Department, Medical School, State University of Rio de Janeiro, Rio de Janeiro, Brazil
  2. Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, Brazil
  3. Takeda Pharmaceuticals, Sao Paulo, Brazil
Gastroenterology Rev 2023; 18 (1): 47–55
DOI: https://doi.org/10.5114/pg.2022.116673
Online publish date: 2022/08/15
View full text Get citation
 
PlumX metrics:
Introduction
A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency – ANVISA.

Aim
This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate.

Material and methods
A literature search was conducted through April–May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate.

Results
Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control – particularly at night – using currently available PPIs, this new drug class is promising.

Conclusions
This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.

keywords:

gastroesophageal reflux, antacids, proton pump inhibitors, P-CABs, vonoprazan
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.